Associate Professor and Director, Antivirals and vaccines research Program
Yale School of Medicine
Disclosure(s): Gilead Sciences, Inc.: Advisor/Consultant, Honoraria; GSK/ViiV: Advisor/Consultant, Honoraria; Janssen: Advisor/Consultant; Moderna: Advisor/Consultant, Honoraria
Dr Onyema Ogbuagu, MD FACP FIDSA, is an Associate Professor of Infectious Diseases and Pharmacology at Yale School of Medicine. He is also the Director of the Yale Antivirals and Vaccines Research Program in the Section of Infectious Diseases (since 2017) and has served as a principal investigator on multiple multinational phase 1-4 studies including FDA registrational trials for novel therapeutics for HIV treatment (for both treatment naïve and treatment-experienced people with HIV) including CAPELLA; HIV preventions trials such as the DISCOVER and PURPOSE-2 trials as well as COVID-19 treatment and vaccines studies. As the Yale site lead for International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)’s Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE) studies, he oversees the COVID-19 treatment study portfolio and his research program is also involved in trials of vaccines being developed for a host of other viral and bacterial infections. Dr Ogbuagu is also an affiliate of the Yale Institute of Global Health where he has led or supported large-scale capacity-building medical education and training initiatives in Rwanda and Liberia focused on infectious diseases as well as research capacity building with current focus on HIV prevention for adolescent girls and young women at risk for HIV in Liberia. He also provided technical assistance to Liberia’s National AIDS-STI control program on integrated guidelines for HIV treatment, care and prevention. His work has been/is supported by World Bank, NIAID, USAID/National Academy of Sciences, and Health Resources and Services Administration (HRSA). Dr Ogbuagu is also a practicing clinician and provides expert consultation for complex HIV treatment cases, as well as viral hepatitis.